NCT00774267 is a clinical trial of BZA 20 mg/CE 0.45 mg in Osteoporosis, sponsored by Pfizer.

Who is sponsoring NCT00774267?

NCT00774267 is sponsored by Pfizer.

What drugs are being tested in NCT00774267?

Interventions in NCT00774267: BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo.

What condition does NCT00774267 study?

NCT00774267 studies Osteoporosis.

Is NCT00774267 still recruiting?

NCT00774267 is currently completed. Last updated 10 March 2014.

Are results published for NCT00774267?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-03-10 · How we verify

NCT00774267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation Of Changes In Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene And Placebo In Postmenopausal Women: An Ancillary Study Of Protocol 3115A1-303-WW

Completed Results posted Last updated 10 March 2014

What this trial tests

trial testing BZA 20 mg/CE 0.45 mg in Osteoporosis in 507 participants. Completed in 1 April 2010.

Timeline

1 January 2009

Primary endpoint
1 April 2010

1 April 2010

Quick facts

Lead sponsor	Pfizer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	507
Start date	1 January 2009
Primary completion	1 April 2010
Estimated completion	1 April 2010
Sites	26 locations across United States, Brazil, Netherlands, Norway

Drugs / interventions tested

BZA 20 mg/CE 0.45 mg — full drug profile →
BZA 20 mg/CE 0.625 mg — full drug profile →
Raloxifene 60 mg
Placebo

Conditions studied

Osteoporosis — all drugs for Osteoporosis →

Sponsor

Pfizer — full company profile →

Who can join

Adults 40 to 75, female only, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent Change From Baseline in Mammographic Breast Density at Month 24
Time frame: primary study baseline, Month 24
The digitized mammogram pairs were analyzed by a single trained radiologist who determined the density of the breast using software. The only left craniocaudal view was used for assessing breast density.

Sponsor's own description

The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH, Wahler J, Suh N. · · 2016 · cited 95× · PMID 26840088 · DOI 10.18632/oncotarget.7102
IL-6: The Link Between Inflammation, Immunity and Breast Cancer.
Chen J, Wei Y, Yang W, Huang Q, et al · · 2022 · cited 72× · PMID 35924148 · DOI 10.3389/fonc.2022.903800

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

NCT07027306 — The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fract · recruiting
NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
NCT06731608 — OsteoPorotic fracTure preventION System (OPTIONS) Research Study · NA · recruiting
NCT07281586 — Step-down Therapy After Long-term Osteoporosis Treatment · Phase 4 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00774267 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 10 March 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00774267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing